London's equity capital markets, including the Alternative Investment Market (AIM), have seen a surge in popularity from not just UK but also international issuers in the recent past and are a viable source of stable, long-term institutional capital for many growth businesses. Indeed, London is home to more than 50 US-based companies, including life science related companies such as Verseon, PureTech and recent addition Maxcyte.
Join us for a breakfast seminar and panel discussion with leading experts from the London Stock Exchange, KPMG and Penningtons Manches to hear more about current equity issuance conditions and the opportunities London can offer UK, US and international growth companies, where we will also be joined by senior management from Verseon, which executed a $100m IPO on AIM just over a year ago, to hear their experiences of listing on AIM.
Privacy & Cookies Policy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.